Cargando…
P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430789/ http://dx.doi.org/10.1097/01.HS9.0000846888.40027.b8 |
| _version_ | 1784779873179402240 |
|---|---|
| author | Ali, H. Kishtagari, A. Maher, K. Mohan, S. Mazumder, A. Chamoun, K. Karasik, I. Sbar, E. Dugom, L. Tamir, S. Wang, X. Prchal, J. Tantravahi, S. |
| author_facet | Ali, H. Kishtagari, A. Maher, K. Mohan, S. Mazumder, A. Chamoun, K. Karasik, I. Sbar, E. Dugom, L. Tamir, S. Wang, X. Prchal, J. Tantravahi, S. |
| author_sort | Ali, H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430789 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94307892022-08-31 P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS Ali, H. Kishtagari, A. Maher, K. Mohan, S. Mazumder, A. Chamoun, K. Karasik, I. Sbar, E. Dugom, L. Tamir, S. Wang, X. Prchal, J. Tantravahi, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430789/ http://dx.doi.org/10.1097/01.HS9.0000846888.40027.b8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Ali, H. Kishtagari, A. Maher, K. Mohan, S. Mazumder, A. Chamoun, K. Karasik, I. Sbar, E. Dugom, L. Tamir, S. Wang, X. Prchal, J. Tantravahi, S. P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title | P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title_full | P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title_fullStr | P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title_full_unstemmed | P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title_short | P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS |
| title_sort | p1005: a phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430789/ http://dx.doi.org/10.1097/01.HS9.0000846888.40027.b8 |
| work_keys_str_mv | AT alih p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT kishtagaria p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT maherk p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT mohans p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT mazumdera p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT chamounk p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT karasiki p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT sbare p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT dugoml p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT tamirs p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT wangx p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT prchalj p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis AT tantravahis p1005aphase1openlabeldoseescalationstudyofselinexorplusruxolitinibinpatientswithtreatmentnaivemyelofibrosis |